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suggest that the community pharmacists in Pakistan do have concerns regarding 
their present clinical and professional role. Besides, this study also suggested that 
community pharmacists need to be more proactive and professional in collaboration 
with other health care professionals.
PHP9
Knowledge, attitude and PercePtions of HosPital PHarmacists 
towards PHarmacists led interventions to reduce adverse drug 
reactions, drug interactions, and PHarmaceutical care issues 
towards better PHarmaceutical care Planning: a qualitative 
insigHt from PaKistan
Iqbal M.S.1, Iqbal M.W.2, Iqbal M.Z.3, Akhtar N.4, Ping N.Y.3, Bahari M.B.3
1Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical 
Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 
2Faculty of Law, University of Malaya, Kualalumpur, Malaysia, 3Department of Clinical Pharmacy 
& Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 4Faculty of 
Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan
OBJECTIVES: To investigate hospital pharmacists’ Knowledge, Attitude and 
Perceptions (KAP) regarding pharmacists-led interventions to reduce Adverse Drug 
Reactions (ADRs), Drug Interactions (DIs), and Pharmaceutical Care Issues (PCIs) 
towards better pharmaceutical care planning in Pakistan. METHODS: A prospective, 
cross-sectional and self-administered questionnaire based study was conducted in 
tertiary care public hospitals in Pakistan. Only registered hospital pharmacists were 
approached to obtain data regarding their KAP towards pharmacists-led interven-
tions to reduce ADRs, DIs, and PCIs towards better pharmaceutical care planning. All 
obtained data were analyzed using descriptive and inferential statistics. RESULTS: 
More than two thirds of the hospital pharmacists (75%) rated physicians as the first 
person to contact in case of any ADRs, DIs, and PCIs. Nevertheless, very poor KAP 
was observed towards pharmacist’s professional role in addressing ADRs, DIs, and 
PCIs (79%). Unexpectedly, 42% of them were not having appropriate knowledge 
towards pharmacists’ role in addressing ADRs, DIs, and PCIs in PCP (79%). A total of 
72.1% reported that they are familiar with the procedure of reporting ADRs. A total 
of 89.1% of the respondents agreed that safe, effective and patient-centered PCP 
plays an important role in patient safety and professional healthcare. In multivari-
ate logistic regression, statistical correlations showed that gender and age were the 
persuasive predictors for the studied model. CONCLUSIONS: The findings from this 
study endorse that the knowledge of hospital pharmacists in Pakistan regarding 
their role to reduce ADRs, DIs, and PCIs towards better pharmaceutical care plan-
ning was not satisfactory. Their attitude towards learning of latest methods and 
procedures to address ADRs, DIs, and PCIs was satisfactory. However, pharmacists 
need to be more proactive and professional in playing their professional role towards 
better patient care.
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OBJECTIVES: We assessed trends in approvals of new molecular entities (NME) and 
new therapeutic biologic license applications (BLA) in the US in the period 1980-2014 
by country of incorporation of the sponsor company of the application. METHODS: 
Regulatory information for NMEs and BLA approved in the study period was derived 
from the FDA, and the country of incorporation of the sponsor companies at the date 
of drug approval was extracted from Lexis-Nexis, companies’ webpages and financial 
reports. Drugs were classified using the WHO anatomical therapeutic chemical clas-
sification system. Descriptive statistics and chi-square tests were conducted in the 
study. RESULTS: The FDA approved 103 BLA and 866 NME during the period 1980-2014. 
Five countries had an average of at least 1 BLA/NME approved per year during the 
study period: US (57.9% of all approvals), UK (10.6%), Switzerland (10.0%), Germany 
(7.1%), and Japan (3.7%). The percentage of drugs approved by US companies ranged 
from 65.9% for antiinfectives for systemic use to 38.9% for sensory organs. US com-
panies sponsored a higher number of BLA (76.7%) than NME (55.7%) (p< 0.001). Drugs 
approved by US companies varied from 62.7% in the 1980s, 56.6% in the 1990s, 58.2% in 
the 2000s, and 53.2% in the period 2010-2014. The therapeutic classes with the largest 
percentage of approvals for each country of incorporation were: dermatologicals in the 
UK (27.0% of all approvals), sensory organs in Switzerland (38.9%), respiratory system 
in Germany (18.4%), nervous system in Japan (9.4%), and genitourinary system and sex 
hormones in France (6.1%). US companies sponsored a larger percentage of orphan 
(64.8%) than non-orphan drugs (54.6%) (p< 0.001). CONCLUSIONS: Approximately 90% 
of all new drugs approved by the FDA were sponsored by companies incorporated 
in US, UK, Switzerland, Germany, and Japan, indicating that pharmaceutical R&D is 
concentrated in a few countries.
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OBJECTIVES: The Essential Medicine Policy (EMP) was implemented to improve 
the affordability of medicines and reduce patients’ economic burden in 2009 along 
with the new round of health care reform in China. This study is to evaluate the 
effects of EMP on patients’ health care utilization and spending. METHODS: Urban 
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OBJECTIVES: This research aims to examine whether minority and/or low-income 
patients are slower to stop use of a particular medical treatment when there is 
new evidence of safety risks. METHODS: We examine the demand response of 11 
chronic medications that received first-time major safety warnings (including black 
box warnings) from the Food and Drug Administration (FDA) between July 2006 -- 
December 2009. We restrict the sample to medications that experienced decreased 
utilization post-warning and followed patients who were users of at least one of the 
11 medications. Selected Medicare beneficiaries were 18 years or older (n = 549,645), 
drawn from a random 20% sample of Medicare Part D claims data. A pooled multi-
variate logistic regression was performed on the likelihood of these patients stop-
ping use post warning (defined as having no claims of the medication between 180 
-- 360 days post warnings), controlling for patient demographics, Medicare plan type, 
new user status (naive patients or not), medication and state fixed effects. RESULTS: 
Preliminary analyses suggest that Hispanics and blacks were more likely to stop tak-
ing a medication compared to whites (ORs= 1.160 and 1.122, respectively, p< 0.001). 
By contrast, Medicare beneficiaries eligible to receive medications at little or no 
cost, i.e. dual-eligibiles and those who received low income subsidies, were less 
likely to stop than non-subsidized beneficiaries (ORs = 0.790 and 0.792 respectively, 
p< 0.001). Users who initiated their medications within 6 months before the safety 
warnings were the most likely to stop use in the post-warning period (OR = 3.759, 
p< 0.001). CONCLUSIONS: The findings suggest that socio-economic status is associ-
ated with modestly longer delays in stopping drug therapy with recent medication 
safety warnings. Specifically, low-income patients who are subsidized beneficiaries 
are less likely to stop using medications that received safety warnings and therefore 
may be subject to greater harm from adverse drug effects.
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OBJECTIVES: Medication Guides are patient-directed, Food and Drug Administration 
(FDA)-approved labeling intended to provide risk and safe-use information for 
prescription medications in easy-to-read, lay language. They were introduced to 
help patients understand and manage risks and maximize benefit from products 
by aiding in decision-making and helping improve adherence to and appropri-
ate use of medications. This review was designed to assess whether patients are 
receiving medication guides per federal regulations and are able to use them as 
intended. METHODS: Knowledge, Attitudes, and Behavior (KAB) survey results in 
a heterogeneous sample of FDA-mandated REMS were reviewed to assess under-
standing of key risk messages (KRM) and receipt, reading, and understanding of 
medication guides. Results were calculated individually and compared across 
surveys. RESULTS: The review includes results from 36 patient KAB surveys for 
products in 8 therapeutic areas. Sample sizes ranged from 10-628 respondents per 
survey. Receipt: Median 89.3% (range 58.1-99.6%) of respondents reported receiving a 
medication guide. Reading: Median 93.1% (range 77.0-100.0%) of respondents report-
ing receiving a medication guide reported reading at least some of it. Understanding: 
Median 93.7% (range 36.8-100.0%) of respondents reported understanding all or 
most of what they read in the medication guide. Median 98.3% (range 64.6-100.0%) 
of respondents reported they understood all or most of what they read after having 
someone explain the information. In an objective assessment of understanding KRM 
of medication guides, median 72.4% (range 1.2-100.0%) of respondents answered 
questions correctly. CONCLUSIONS: This review demonstrates the inconsistency of 
usability of medication guides for the purposes intended as shown by the range of 
responses, particularly objective assessment of KRM understanding. Usability may 
be limited by incomplete distribution and inadequate risk communication. Data 
will be presented to discuss differences in reported and demonstrated understand-
ing and possible reasons why patients may be unable to use medication guides as 
they are intended.
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OBJECTIVES: To investigate community pharmacists’ perception towards inter 
professional learning (IPL), continue professional development (CPD) programs 
and their current clinical and professional role towards patient care in Pakistan’s 
health care system. METHODS: This study was conducted on community phar-
macists from different cities of the biggest province of Pakistan, the Punjab. Data 
was collected by convenient sampling method from all major cities of the province. 
Different statistical tests were used to analyze the obtained data. RESULTS: Around 
93.9% of the community pharmacists were involved in prescription filling, refilling 
and patient counseling in the Punjab, Pakistan. They all were willing to take part 
in IPL, CPDs and patient safety programs but majority of the pharmacist (82.8%) 
conveyed that their current role is more focusing towards the store manager, buy-
ing and selling of the medicines and inventory control. Surprisingly, 75% of them 
were not aware about IPL and CPDs. CONCLUSIONS: The findings from this study 
